Two Sigma Investments
SCNI

Two Sigma Investments’s Scinai Immunotherapeutics SCNI Stock Holding History

Two Sigma Investments’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-269
Closed -$76K – 4203
2020
Q4 		$76K Buy
+269
New +$326K ﹤0.01% 3228

Other funds holding SCNI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Two Sigma Investments's SCNI Position: Q1 2021 in Review

Two Sigma Investments sold out of Scinai Immunotherapeutics (SCNI) in Q1 2021, closing a stake of 269 shares — an estimated $76K sold.

Two Sigma Investments first reported a position in SCNI in Q4 2020 and held it in 1 quarter. The position peaked at $76K in Q4 2020. 18 funds tracked by Wall St. Rank hold SCNI as of Q1 2021.

  • Two Sigma Investments reported no remaining Scinai Immunotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Two Sigma Investments sold 269 Scinai Immunotherapeutics shares in Q1 2021, an estimated $76K.
  • Two Sigma Investments first reported a position in Scinai Immunotherapeutics in Q4 2020 and held it in 1 quarter.
  • Two Sigma Investments's Scinai Immunotherapeutics position peaked at $76K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2021.

Based on Two Sigma Investments's 13F filing for Q1 2021, filed 17 May 2021.